**SUPPLEMENTARY FILE 1: SUBGROUP ANALYSIS OF MEAN WEIGHTS, SCORES AND VALUE ESTIMATES FOR NINTEDANIB VERSUS PLACEBO**

**Supplementary Table 1.1: Mean weights and ranges (min-max) by subgroup, 100-point distribution, non-IPF PF-ILD and SSc-ILD**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Criteria** | **Global**  **(n=12)** | **Clinicians**  **(n=4)** | **Patients**  **(n=2)** | **Managers**  **(n=2)** | **Pharmacists**  **(n=2)** | **Others**  **(n=2)** |
| **1. Disease severity** | 18.4 (8.4-30.0) | 20.5 (17.0-25.0) | 15.6 (11.1-20.0) | 18.6 (16.1-21.1) | 14.7 (8.4-21.1) | 20.6 (11.1-30.0) |
| **2. Unmet needs** | 14.0 (8.9-21.1) | 16.3 (10.0-20.0) | 11.9 (8.9-15.0) | 15.9 (10.8-21.1) | 10.0 (9.5-10.5) | 13.3 (10.0-16.7) |
| **3. Comparative effectiveness / efficacy** | 9.8 (0.0-16.7) | 10.0 (5.0-15.0) | 8.9 (7.8-10.0) | 10.6 (10.5-10.8) | 11.1 (10.5-11.6) | 8.3 (0.0-16.7) |
| **4. Comparative safety / tolerability** | 10.4 (5.0-25.0) | 8.8 (5.0-10.0) | 7.8 (5.6-10.0) | 8.0 (5.3-10.8) | 11.1 (10.5-11.6) | 18.1 (11.1-25.0) |
| **5. Comparative PRO** | 5.8 (0.0-11.1) | 2.5 (0.0-5.0) | 10.6 (10.0-11.1) | 8.0 (5.4-.10.5) | 8.9 (7.4-10.5) | 2.5 (0.0-5.0) |
| **6. Type of therapeutic benefit** | 13.2 (10.0-20.0) | 13.3 (10.0-15.0) | 13.1 (11.1-15.0) | 13.3 (10.5-16.1) | 10.5 (10.5-10.5) | 15.6 (11.1-20.0) |
| **7. Cost of intervention** | 7.8 (0.0-16.7) | 6.3 (5.0-10.0) | 4.4 (0.0-8.9) | 13.3 (10.5-16.1) | 8.4 (5.3-11.6) | 8.3 (0.0-16.7) |
| **8. Other medical costs** | 4.7 (0.0-10.0) | 3.0 (0.0-5.0) | 7.5 (5.0-10.0) | 5.3 (5.3-5.4) | 6.8 (5.3-8.4) | 2.8 (0.0-5.6) |
| **9. Non-medical costs** | 2.5 (0.0-6.3) | 0.5 (0.0-2.0) | 5.3 (5.0-5.6) | 2.7 (0.0-5.4) | 5.8 (5.3-6.3) | 0.0 (0.0-0.0) |
| **10. Quality of evidence** | 9.0 (2.2-20.0) | 15.0 (10.0-20.0) | 8.1 (5.0-11.1) | 2.7 (2.2-3.2) | 7.9 (5.3-10.5) | 5.3 (5.0-5.6) |
| **11. Expert consensus / CPG** | 4.4 (0.0-8.9) | 4.0 (0.0-6.0) | 6.9 (5.0-8.9) | 1.6 (1.1-2.1) | 4.7 (4.2-5.3) | 5.3 (5.0-5.6) |
| **Total** | **100.0** | **100.0** | **100.0** | **100.0** | **100.0** | **100.0** |

*Note:* A 100 points distribution was used, where the experts assigned a weight to each criterion, given the sum of the weights resulted in 100

*Non-IPF PF-ILD*: non-idiopathic progressive fibrosing interstitial lung disease. *SSc-ILD*: systemic sclerosis-associated interstitial lung disease. *PRO*: patient reported outcomes. *CPG*: clinical practice guidelines

**Supplementary Table 1.2: Mean scores and ranges (min-max) by subgroup, non-IPF PF-ILD**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Criteria** | **Global**  **(n=12)** | **Clinicians**  **(n=4)** | **Patients**  **(n=2)** | **Managers**  **(n=2)** | **Pharmacists**  **(n=2)** | **Others**  **(n=2)** |
| **1. Disease severity (A)** | 4.4 (3.0-5.0) | 4.5 (4.0-5.0) | 4.0 (3.0-5.0) | 4.5 (4.0-5.0) | 4.5 (4.0-5.0) | 4.5 (4.0-5.0) |
| **2. Unmet needs (A)** | 4.3 (3.0-5.0) | 4.3 (4.0-5.0) | 3.5 (3.0-4.0) | 4.5 (4.0-5.0) | 4.5 (4.0-5.0) | 4.5 (4.0-5.0) |
| **3. Comparative effectiveness / efficacy (R)** | 3.2 (2.0-4.0) | 3.0 (3.0-3.0) | 3.5 (3.0-4.0) | 3.5 (3.0-4.0) | 3.5 (3.0-4.0) | 2.5 (2.0-3.0) |
| **4. Comparative safety / tolerability (R)** | 0.1 (-3.0-+4.0) | -2.5 (-3.0-2.0) | 4.0 (4.0-4.0) | 1.5 (-1.0-+4.0) | -1.0 (-1.0-1.0) | 1.0 (-1.0-+3.0) |
| **5. Comparative PRO (R)** | 1.6 (0.0-3.0) | 1.5 (0.0-2.0) | 3.0 (3.0-3.0) | 1.5 (1.0-2.0) | 1.0 (0.0-2.0) | 2.0 (1.0-3.0) |
| **6. Type of therapeutic benefit (A)** | 2.7 (2.0-4.0) | 3.0 (3.0-3.0) | 3.5 (3.0-4.0) | 2.5 (2.0-3.0) | 2.0 (2.0-2.0) | 2.0 (2.0-2.0) |
| **7. Cost of intervention (R)** | -3.2 (-5.0-0.0) | -3.8 (-5.0-3.0) | -2.0 (-3.0-1.0) | -4.5 (-5.0-4.0) | -3.0 (-4.0-2.0) | -2.0 (-4.0-0.0) |
| **8. Other medical costs (R)** | 2.0 (0.0-3.0) | 1.5 (0.0-2.0) | 3.0 (3.0-3.0) | 3.0 (3.0-3.0) | 1.5 (1.0-2.0) | 1.5 (0.0-3.0) |
| **9. Non-medical costs (R)** | 1.2 (-2.0-+3.0) | 1.0 (-2.0-+3.0) | 1.5 (0.0-3.0) | 0.5 (-2.0-3.0) | 1.5 (1.0-2.0) | 1.5 (0.0-3.0) |
| **10. Quality of evidence (A)** | 3.7 (2.0-5.0) | 4.3 (3.0-5.0) | 3.5 (3.0-4.0) | 4.0 (4.0-4.0) | 3.0 (2.0-4.0) | 3.0 (3.0-3.0) |
| **11. Expert consensus / CPG (A)** | 2.7 (1.0-4.0) | 3.3 (2.0-4.0) | 1.5 (1.0-2.0) | 3.5 (3.0-4.0) | 2.0 (1.0-3.0) | 2.5 (2.0-3.0) |

*Notes:* **(A)**The scores for the **absolute criteria** (those that did not involve comparisons with placebo) could range from 0 to 5, 0 being the lowest value and 5 the highest. **(R)** The scores for the **relative criteria** (those involving comparison with placebo), could range from -5 to 5 to reflect the full range of comparative effects.

*Non-IPF PF-ILD*: non-idiopathic progressive fibrosing interstitial lung disease. *PRO*: patient reported outcomes. *CPG*: clinical practice guidelines

**Supplementary Table 1.3: Mean scores and ranges (min-max) by subgroup, SSc-ILD**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Criteria** | **Global**  **(n=12)** | **Clinicians**  **(n=4)** | **Patients**  **(n=2)** | **Managers**  **(n=2)** | **Pharmacists**  **(n=2)** | **Others**  **(n=2)** |
| **1. Disease severity (A)** | 4.1 (3.0-5.0) | 4.0 (4.0-4.0) | 4.5 (4.0-5.0) | 4.5 (4.0-5.0) | 4.0 (4.0-4.0) | 3.5 (3.0-4.0) |
| **2. Unmet needs (A)** | 3.9 (3.0-5.0) | 3.8 (3.0-4.0) | 4.0 (4.0-4.0) | 4.0 (4.0-4.0) | 4.0 (4.0-4.0) | 4.0 (3.0-5.0) |
| **3. Comparative effectiveness / efficacy (R)** | 2.7 (2.0-3.0) | 2.5 (2.0-3.0) | 3.0 (3.0-3.0) | 3.0 (3.0-3.0) | 3.0 (3.0-3.0) | 2.0 (2.0-2.0) |
| **4. Comparative safety / tolerability (R)** | -2.1 (-3.0-1.0) | -2.8 (-3.0-2.0) | -2.5 (-3.0-2.0) | -1.5 (-2.0-1.0) | -1.5 (-2.0-1.0) | -1.5 (-2.0-1.0) |
| **5. Comparative PRO (R)** | 0.3 (-1.0-+3.0) | -0.5 (-1.0-0.0) | 1.5 (0.0-3.0) | 1.0 (1.0-1.0) | -0.5 (-1.0-0.0) | 0.5 (0.0-1.0) |
| **6. Type of therapeutic benefit (A)** | 2.3 (1.0-3.0) | 2.8 (2.0-3.0) | 2.0 (1.0-3.0) | 3.0 (3.0-3.0) | 2.0 (2.0-2.0) | 1.5 (1.0-2.0) |
| **7. Cost of intervention (R)** | -3.3 (-5.0-2.0) | -3.5 (-5.0-3.0) | -3.0 (-3.0-3.0) | -4.0 (-4.0-4.0) | -3.0 (-3.0-3.0) | -2.5 (-3.0-2.0) |
| **8. Other medical costs (R)** | 1.8 (0.0-4.0) | 1.0 (0.0-2.0) | 2.5 (2.0-3.0) | 3.0 (3.0-3.0) | 2.5 (1.0-4.0) | 0.5 (0.0-1.0) |
| **9. Non-medical costs (R)** | 1.5 (0.0-3.0) | 1.5 (0.0-3.0) | 3.0 (3.0-3.0) | 2.0 (2.0-2.0) | 1.0 (1.0-1.0) | 0.0 (0.0-0.0) |
| **10. Quality of evidence (A)** | 3.3 (2.0-4.0) | 3.5 (3.0-4.0) | 3.5 (3.0-4.0) | 3.5 (3.0-4.0) | 3.5 (3.0-4.0) | 2.5 (2.0-3.0) |
| **11. Expert consensus / CPG (A)** | 2.3 (1.0-4.0) | 2.5 (1.0-4.0) | 3.0 (3.0-3.0) | 2.0 (1.0-3.0) | 2.0 (1.0-3.0) | 1.5 (1.0-2.0) |

*Notes:* **(A)**The scores for the **absolute criteria** (those that did not involve comparisons with placebo) could range from 0 to 5, 0 being the lowest value and 5 the highest. **(R)** The scores for the **relative criteria** (those involving comparison with placebo), could range from -5 to 5 to reflect the full range of comparative effects.

*SSc-ILD*: systemic sclerosis-associated interstitial lung disease. *PRO*: patient reported outcomes. *CPG*: clinical practice guidelines

**Supplementary Table 1.4: Mean value estimates and ranges (min-max) by subgroup, 100-points distribution, non-IPF PF-ILD**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Criteria** | **Global**  **(n=12)** | **Clinicians**  **(n=4)** | **Patients**  **(n=2)** | **Managers**  **(n=2)** | **Pharmacists**  **(n=2)** | **Others**  **(n=2)** |
| **1. Disease severity (A)** | 0.17 (0.07-0.30) | 0.18 (0.16-0.20) | 0.13 (0.07-0.20) | 0.17 (0.13-0.21) | 0.14 (0.07-0.21) | 0.19 (0.09-0.30) |
| **2. Unmet needs (A)** | 0.12 (0.05-0.21) | 0.14 (0.08-0.20) | 0.09 (0.05-0.12) | 0.15 (0.09-1.21) | 0.09 (0.08-0.09) | 0.12 (0.10-0.13) |
| **3. Comparative effectiveness / efficacy (R)** | 0.06 (0.00-0.09) | 0.06 (0.03-0.09) | 0.06 (0.06-0.06) | 0.07 (0.06-0.09) | 0.08 (0.06-0.09) | 0.03 (0.00-0.07) |
| **4. Comparative safety / tolerability (R)** | 0.00 (-0.06-0.15) | -0.05 (-0.06-0.02) | 0.06 (0.04-0.08) | 0.01 (-0.02-0.04) | -0.02 (-0.02-0.02) | 0.06 (-0.02-0.15) |
| **5. Comparative PRO (R)** | 0.02 (0.00-0.07) | 0.01 (0.00-0.02) | 0.06 (0.06-0.07) | 0.02 (0.02-0.02) | 0.02 (0.00-0.04) | 0.02 (0.00-0.03) |
| **6. Type of therapeutic benefit (A)** | 0.07 (0.04-0.12) | 0.08 (0.06-0.09) | 0.09 (0.07-0.12) | 0.07 (0.04-0.10) | 0.04 (0.04-0.04) | 0.06 (0.04-0.08) |
| **7. Cost of intervention (R)** | -0.06 (-0.13-0.00) | -0.05 (-0.08-0.03) | -0.01 (-0.02-0.00) | -0.12 (-0.13-0.11) | -0.06 (-0.09-0.02) | -0.07 (-0.13-0.00) |
| **8. Other medical costs (R)** | 0.02 (0.00-0.06) | 0.01 (0.00-0.02) | 0.05 (0.03-0.06) | 0.03 (0.03-0.03) | 0.02 (0.02-0.02) | 0.00 (0.00-0.00) |
| **9. Non-medical costs (R)** | 0.00 (-0.02-0.03) | 0.00 (0.00-0.01) | 0.02 (0.00-0.03) | -0.01 (-0.02-0.00) | 0.02 (0.01-0.02) | 0.00 (0.00-0.00) |
| **10. Quality of evidence (A)** | 0.07 (0.02-0.20) | 0.13 (0.09-0.20) | 0.05 (0.04-0.07) | 0.02 (0.02-0.03) | 0.05 (0.02-0.08) | 0.03 (0.03-0.03) |
| **11. Expert consensus / CPG (A)** | 0.02 (0.00-0.04) | 0.03 (0.00-0.04) | 0.02 (0.02-0.02) | 0.01 (0.01-0.01) | 0.02 (0.01-0.03) | 0.03 (0.02-0.03) |
| **Total** | **0.50** **(0.23-0.76)** | **0.54 (0.49-0.59)** | **0.62 (0.49-0.76)** | **0.43 (0.31-0.55)** | **0.40 (0.32-0.47)** | **0.48 (0.23-0.72)** |

*Notes:* **(A)**The value estimates for the **absolute criteria** (those that did not involve comparisons with placebo) could range from 0 to 1, 0 being the lowest value and 1 the highest. **(R)** The value estimates for the **relative criteria** (those involving comparison with placebo), could range from -1 to 1 to reflect the full range of comparative effects.

*Non-IPF PF-ILD*: non-idiopathic progressive fibrosing interstitial lung disease. *PRO*: patient reported outcomes. *CPG*: clinical practice guidelines

**Supplementary Table 1.5: Mean value estimates and ranges (min-max) by subgroup, 100-points distribution, SSc-ILD**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Criteria** | **Global**  **(n=12)** | **Clinicians**  **(n=4)** | **Patients**  **(n=2)** | **Managers**  **(n=2)** | **Pharmacists**  **(n=2)** | **Others**  **(n=2)** |
| **1. Disease severity (A)** | 0.15 (0.07-0.24) | 0.16 (0.14-0.20) | 0.14 (0.09-0.20) | 0.17 (0.13-0.21) | 0.12 (0.07-0.17) | 0.15 (0.07-0.24) |
| **2. Unmet needs (A)** | 0.11 (0.06-0.17) | 0.13 (0.06-0.16) | 0.10 (0.07-0.12) | 0.13 (0.09-0.17) | 0.08 (0.08-0.08) | 0.10 (0.10-0.10) |
| **3. Comparative effectiveness / efficacy (R)** | 0.05 (0.00-0.07) | 0.05 (0.03-0.06) | 0.05 (0.05-0.06) | 0.06 (0.06-0.06) | 0.07 (0.06-0.07) | 0.03 (0.00-0.07) |
| **4. Comparative safety / tolerability (R)** | -0.04 (-0.10-0.02) | -0.05 (-0.06-0.03) | -0.04 (-0.04-0.03) | -0.02 (-0.02-0.02) | -0.03 (-0.04-0.02) | -0.06 (-0.10-0.02) |
| **5. Comparative PRO (R)** | 0.01 (-0.02-+0.06) | 0.00 (-0.01-0.00) | 0.03 (0.00-0.06) | 0.02 (0.01-0.02) | -0.01 (-0.02-0.00) | 0.01 (0.00-0.01) |
| **6. Type of therapeutic benefit (A)** | 0.06 (0.02-0.10) | 0.07 (0.04-0.09) | 0.06 (0.02-0.09) | 0.08 (0.06-0.10) | 0.04 (0.04-0.04) | 0.05 (0.02-0.08) |
| **7. Cost of intervention (R)** | -0.05 (-0.13-0.00) | -0.04 (-0.06-0.03) | -0.03 (-0.05-0.00) | -0.11 (-0.13-0.08) | -0.05 (-0.07-0.03) | -0.05 (-0.10-0.00) |
| **8. Other medical costs (R)** | 0.02 (0.00-0.04) | 0.01 (0.00-0.02) | 0.04 (0.03-0.04) | 0.03 (0.03-0.03) | 0.03 (0.02-0.04) | 0.00 (0.00-0.00) |
| **9. Non-medical costs (R)** | 0.01 (0.00-0.03) | 0.00 (0.00-0.01) | 0.03 (0.03-0.03) | 0.01 (0.00-0.02) | 0.01 (0.01-0.01) | 0.00 (0.00-0.00) |
| **10. Quality of evidence (A)** | 0.06 (0.02-0.12) | 0.10 (0.08-0.12) | 0.05 (0.04-0.07) | 0.02 (0.02-0.02) | 0.06 (0.03-0.08) | 0.03 (0.02-0.03) |
| **11. Expert consensus / CPG (A)** | 0.02 (0.00-0.05) | 0.02 (0.00-0.04) | 0.04 (0.03-0.05) | 0.01 (0.00-0.01) | 0.02 (0.01-0.03) | 0.02 (0.01-0.02) |
| **Total** | **0.40 (0.18-0.62)** | **0.46 (0.42-0.52)** | **0.48 (0.34-0.62)** | **0.39 (0.31-0.48)** | **0.33 (0.30-0.36)** | **0.27 (0.18-0.37)** |

*Notes:* **(A)**The value estimates for the **absolute criteria** (those that did not involve comparisons with placebo) could range from 0 to 1, 0 being the lowest value and 1 the highest. **(R)** The value estimates for the **relative criteria** (those involving comparison with placebo), could range from -1 to 1 to reflect the full range of comparative effects.

*SSc-ILD*: systemic sclerosis-associated interstitial lung disease. *PRO*: patient reported outcomes. *CPG*: clinical practice guidelines